SEC Comment Letter 0000000000-24-007161 to NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: June 25, 2024 · CIK: 0001389545 · Accession: 0000000000-24-007161

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-280423

Date

June 25, 2024

Author

Division of Corporation Finance

Form

UPLOAD

Company

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

United States securities and exchange commission logo June 25, 2024 Justin M. Hall Chief Executive Officer and General Counsel NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608

Re: NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 21, 2024 File No. 333-280423

Dear Justin M. Hall:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                        June 25, 2024

       Justin M. Hall
       Chief Executive Officer and General Counsel
       NovaBay Pharmaceuticals, Inc.
       2000 Powell Street, Suite 1150
       Emeryville, CA 94608

                                                        Re: NovaBay
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed June 21, 2024
                                                            File No. 333-280423

       Dear Justin M. Hall:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jimmy
McNamara at 202-551-7349 with any questions.

                        Sincerely,

                        Division of Corporation Finance

                        Office of Life Sciences
       cc:                                              Abby E. Brown
</TEXT>
</DOCUMENT>

SecProbe.io